Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut−Brain Interaction): A Rome Foundation Working Team Report

Published on Dec 22, 2017in Gastroenterology17.373
· DOI :10.1053/J.GASTRO.2017.11.279
Douglas A. Drossman103
Estimated H-index: 103
(UNC: University of North Carolina at Chapel Hill),
Jan Tack126
Estimated H-index: 126
(Katholieke Universiteit Leuven)
+ 3 AuthorsLukas Van Oudenhove39
Estimated H-index: 39
(Katholieke Universiteit Leuven)
Sources
Abstract
Background & Aims Central neuromodulators (antidepressants, antipsychotics, and other central nervous system−targeted medications) are increasingly used for treatment of functional gastrointestinal disorders (FGIDs), now recognized as disorders of gut−brain interaction. However, the available evidence and guidance for the use of central neuromodulators in these conditions is scanty and incomplete. In this Rome Foundation Working Team report, a multidisciplinary team summarized available research evidence and clinical experience to provide guidance and treatment recommendations. Methods The working team summarized the literature on the pharmacology of central neuromodulators and their effects on gastrointestinal sensorimotor function and conducted an evidence-based review on their use for treating FGID syndromes. Because of the paucity of data for FGIDs, we included data for non-gastrointestinal painful disorders and specific symptoms of pain, nausea, and vomiting. This information was combined into a final document comprising a synthesis of available evidence and recommendations for clinical use guided by the research and clinical experience of the experts on the committee. Results The evidence-based review on neuromodulators in FGID, restricted by the limited available controlled trials, was integrated with open-label studies and case series, along with the experience of experts to create recommendations using a consensus (Delphi) approach. Due to the diversity of conditions and complexity of treatment options, specific recommendations were generated for different FGIDs. However, some general recommendations include: (1) low to modest dosages of tricyclic antidepressants provide the most convincing evidence of benefit for treating chronic gastrointestinal pain and painful FGIDs and serotonin noradrenergic reuptake inhibitors can also be recommended, though further studies are needed; (2) augmentation, that is, adding a second treatment (adding quetiapine, aripiprazole, buspirone α2δ ligand agents) is recommended when a single medication is unsuccessful or produces side effects at higher dosages; (3) treatment should be continued for 6−12 months to potentially prevent relapse; and (4) implementation of successful treatment requires effective communication skills to improve patient acceptance and adherence, and to optimize the patient−provider relationship. Conclusions Based on systematic and selectively focused review and the consensus of a multidisciplinary panel, we have provided summary information and guidelines for the use of central neuromodulators in the treatment of chronic gastrointestinal symptoms and FGIDs. Further studies are needed to confirm and refine these recommendations.
📖 Papers frequently viewed together
278 Citations
135 Citations
2005
2 Authors (袁孟彪, 顾晓萌)
References174
Newest
#1Eva Szigethy (University of Pittsburgh)H-Index: 38
#2Mitchell R. Knisely (University of Pittsburgh)H-Index: 9
Last. Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
view all 3 authors...
Chronic opioid use is increasing worldwide and has negative effects in the gastrointestinal and central nervous systems. This Review summarizes the evidence and consequences of opioid misuse in gastroenterology, as well as alternative pharmacological and nonpharmacological strategies for pain management in patients with gastrointestinal disorders.
48 CitationsSource
#1Florencia Carbone (Katholieke Universiteit Leuven)H-Index: 14
#2Tim Vanuytsel (Katholieke Universiteit Leuven)H-Index: 29
Last. Jan Tack (Katholieke Universiteit Leuven)H-Index: 50
view all 3 authors...
Background Disturbances of gastric motor function of functional dyspepsia (FD) have been implicated in the pathogenesis of the symptoms, and hence, motility modifying agents are considered for its treatment. Mirtazapine was recently shown to improve symptoms and increase nutrient tolerance in FD patients with weight loss. We aim to evaluate the effect of mirtazapine on gastric sensorimotor function in healthy volunteers (HV). Methods Thirty-one HV underwent an intragastric pressure (IGP) and bar...
20 CitationsSource
#1Paul Moayyedi (McMaster University)H-Index: 115
#2Brian E. Lacy (Dartmouth–Hitchcock Medical Center)H-Index: 54
Last. Nimish Vakil (UW: University of Wisconsin-Madison)H-Index: 75
view all 6 authors...
We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dyspepsia are investigated with upper gastrointestinal
207 CitationsSource
#1W Harley Sobin (United Hospital)H-Index: 1
#2Thomas W. Heinrich (MCW: Medical College of Wisconsin)H-Index: 10
Last. Douglas A. DrossmanH-Index: 103
view all 3 authors...
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they...
26 CitationsSource
#1Kelsey T. Laird (Vandy: Vanderbilt University)H-Index: 13
#2Emily E. Tanner-Smith (Vandy: Vanderbilt University)H-Index: 30
Last. Lynn S. Walker (Monroe Carell Jr. Children's Hospital at Vanderbilt)H-Index: 63
view all 5 authors...
Abstract Previous meta-analyses have shown that psychotherapy improves gastrointestinal symptoms in adults with irritable bowel syndrome (IBS); however, the impact on functioning in daily activities is unknown. Meta-analysis was used to estimate the effect of psychotherapy on mental health and daily functioning in adults with IBS. An extensive literature search located 28 eligible randomized controlled trials (RCTs) providing outcome data for mental health and 18 RCTs providing data for daily fu...
65 CitationsSource
#1Sarah Ballou (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
#2Laurie Keefer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 40
Psychological interventions have been designed and implemented effectively in a wide range of medical conditions, including Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Diseases (IBD). The psychological treatments for IBS and IBD with the strongest evidence base include: cognitive behaviora
63 CitationsSource
#1Ana M. PeiróH-Index: 22
#2César MargaritH-Index: 6
Last. Adrián LLerenaH-Index: 50
view all 3 authors...
2 CitationsSource
#1Marianne Bonnert (KI: Karolinska Institutet)H-Index: 8
#2Ola Olén (KI: Karolinska Institutet)H-Index: 24
Last. Brjánn LjótssonH-Index: 55
view all 13 authors...
Internet-Delivered Cognitive Behavior Therapy for Adolescents With Irritable Bowel Syndrome: A Randomized Controlled Trial
50 CitationsSource
#1Rose A. RuddH-Index: 19
#2Puja SethH-Index: 22
Last. Lawrence SchollH-Index: 5
view all 4 authors...
The U.S. opioid epidemic is continuing, and drug overdose deaths nearly tripled during 1999-2014. Among 47,055 drug overdose deaths that occurred in 2014 in the United States, 28,647 (60.9%) involved an opioid (1). Illicit opioids are contributing to the increase in opioid overdose deaths (2,3). In an effort to target prevention strategies to address the rapidly changing epidemic, CDC examined overall drug overdose death rates during 2010-2015 and opioid overdose death rates during 2014-2015 by ...
1,477 CitationsSource
#1Shinichi Konno (Fukushima Medical University)H-Index: 48
#2Natsuko OdaH-Index: 1
Last. Levent AlevH-Index: 9
view all 4 authors...
A 14-week, randomized, double-blind, multicenter, placebo-controlled study of Japanese patients with chronic low back pain (CLBP) who were randomized to either duloxetine 60 mg once daily or placebo. This study aimed to assess the efficacy and safety of duloxetine monotherapy in Japanese patients with CLBP. In Japan, duloxetine is approved for the treatment of depression, diabetic neuropathic pain, and pain associated with fibromyalgia; however, no clinical study of duloxetine has been conducted...
37 CitationsSource
Cited By113
Newest
Diarrhea-predominant irritable bowel syndrome is a common functional gastrointestinal disorder that manifests with abdominal pain and diarrheal bowel patterns, without structural explanation. Diarrhea-predominant irritable bowel syndrome is a heterogeneous condition resulting from diverse pathophysiologic processes. Treatment strategies with varied mechanisms of action are beneficial in its management. The clinician must become familiar with a multi-dimensional approach to irritable bowel syndro...
Source
#1Umair Akbani (University of Manchester)
#2Dipesh H. Vasant (University of Manchester)H-Index: 10
Source
#1Lin Chang (UCLA: University of California, Los Angeles)H-Index: 73
Source
#1Sophie Parker (University of Sheffield)
#2Olafur S. Palsson (UNC: University of North Carolina at Chapel Hill)H-Index: 50
Last. Imran Aziz (University of Sheffield)H-Index: 21
view all 9 authors...
Background & Aims null Individuals with celiac disease (CD) can experience persisting gastrointestinal symptoms despite adhering to a gluten-free diet (GFD). This may be due to functional gastrointestinal disorders (FGIDs), although there is little data on its prevalence and associated factors. null null null Methods null An online health questionnaire was completed by adult members of Celiac UK in October 2018. The survey included validated questions on Rome IV FGIDs, nongastrointestinal somati...
Source
#1L. SoiferH-Index: 2
Last. Max Schmulson (UNAM: National Autonomous University of Mexico)H-Index: 23
view all 5 authors...
Resumen null null Introduccion y objetivos null Debido a sus diferentes manifestaciones clinicas, la enfermedad por reflujo gastroesofagico (ERGE) requiere de diversas intervenciones diagnosticas y terapeuticas. El objetivo del estudio fue evaluar el grado de acuerdo entre especialistas de Latinoamerica con respecto al manejo de la ERGE. null null null Material y Metodos null Se realizo un estudio transversal mediante la aplicacion de un cuestionario con 42 enunciados (22 respecto a diagnostico ...
Source
#1Laurie Keefer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 40
#2Cynthia W. Ko (UW: University of Washington)H-Index: 25
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 3 authors...
Description null This expert review summarizes approaches to management of pain in disorders of gut–brain interaction. This review focuses specifically on approaches to pain that persist if first-line therapies aimed at addressing visceral causes of pain are unsuccessful. The roles of a therapeutic patient–provider relationship, nonpharmacologic and pharmacologic therapies, and avoidance of opioids are discussed. null null null Methods null This was not a formal systematic review but was based o...
Source
#1Hans Törnblom (University of Gothenburg)H-Index: 33
#2Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose nal...
Source
#1Benjamin Nulsen (UCLA: University of California, Los Angeles)H-Index: 2
#2Wendi LeBrett (UCLA: University of California, Los Angeles)H-Index: 1
Last. Lin Chang (UCLA: University of California, Los Angeles)H-Index: 73
view all 4 authors...
Background null Central neuromodulators are an effective treatment for irritable bowel syndrome (IBS) but may be used less frequently than other therapies. null Aims null To survey gastroenterologists in the United States (US) about their use of neuromodulators in patients with IBS. null Methods null A 23-question survey was distributed to gastroenterologists in the United States. Comparisons in prescribing practices were conducted between (a) gastroenterologists who were "high prescribers" vers...
1 CitationsSource
OBJECTIVE While gastrointestinal (GI) symptoms are very common in patients with major depressive disorder (MDD), few studies have investigated the neural basis behind these symptoms. In this study, we sought to elucidate the neural basis of GI symptoms in MDD patients by analyzing the changes in regional gray matter volume (GMV) and gray matter density (GMD) in brain structure. METHOD Subjects were recruited from 13 clinical centers and categorized into three groups, each of which is based on th...
Source
#1Vivien Hanel (Humboldt University of Berlin)H-Index: 1
#2Martha A Schalla (Humboldt University of Berlin)H-Index: 10
Last. Andreas Stengel (Humboldt University of Berlin)H-Index: 48
view all 3 authors...
OBJECTIVES The prevalence of eating disorders is rising worldwide. The low body weight in anorexia nervosa as well as the increase in body mass index due to binge eating disorder are contributing to a strikingly high morbidity and mortality. In a similar pattern, the prevalence and burden of the disease of functional gastrointestinal disorders such as functional dyspepsia and irritable bowel syndrome is increasing. As gastrointestinal complaints are commonly reported by patients with eating diso...
Source